Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | XmAb20717 |
| Trade Name | |
| Synonyms | XmAb 20717|Vudalimab |
| Drug Descriptions |
XmAb20717 (Vudalimab) is a bispecific antibody that targets both PD-1 (PDCD1) and CTLA4, potentially resulting in increased anti-tumor immune response (Journal for ImmunoTherapy of Cancer 2021;9). |
| DrugClasses | CTLA4 Antibody 33 Immune Checkpoint Inhibitor 150 PD-L1/PD-1 antibody 132 |
| CAS Registry Number | 2329669-72-7 |
| NCIT ID | C150463 |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| Abiraterone + Docetaxel + XmAb20717 | Abiraterone Docetaxel XmAb20717 | 0 | 1 |
| Abiraterone + XmAb20717 | Abiraterone XmAb20717 | 0 | 1 |
| Cabazitaxel + Carboplatin + XmAb20717 | Cabazitaxel Carboplatin XmAb20717 | 0 | 1 |
| Cabazitaxel + XmAb20717 | Cabazitaxel XmAb20717 | 0 | 1 |
| Carboplatin + Pemetrexed Disodium + XmAb20717 | Carboplatin Pemetrexed Disodium XmAb20717 | 0 | 1 |
| Docetaxel + XmAb20717 | Docetaxel XmAb20717 | 0 | 1 |
| Enzalutamide + XmAb20717 | Enzalutamide XmAb20717 | 0 | 1 |
| Olaparib + XmAb20717 | Olaparib XmAb20717 | 0 | 1 |
| Regorafenib + XmAb20717 | Regorafenib XmAb20717 | 0 | 1 |
| XmAb20717 | XmAb20717 | 0 | 6 |